Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, is expanding its BioProcess Innovation Center (BIC) in Research Triangle Park (RTP). Through the expansion, Fujifilm Diosynth Biotechnologies will add approximately 145 skilled positions including researchers and scientists to the RTP site by 2024.
 
The expansion will double Fujifilm Diosynth Biotechnologies’ capacity to support process characterization programs and complements the enhanced and now operational capabilities at Fujifilm Diosynth Biotechnologies’ UK facility, announced in December 2020. In addition, this expansion will allow Fujifilm Diosynth Biotechnologies to better support its partners in discovering the attributes that make each protein unique and better guide clinical process development to create more robust commercial processes. The expansion will include the addition of roughly 89,000 square feet  of laboratory space equipped with comprehensive, state of the art analytical instrumentation, high throughput bioprocessing equipment and automation technologies. The expanded capacity is expected to be operational by mid-2024.
 
“As leaders in process development, we are delighted to be adding this additional capacity to support our growing pipeline of customers,” said Christine Vannais, chief operating officer, Fujifilm Diosynth Biotechnologies, RTP, North Carolina. “The cutting-edge laboratory equipment and automation tools, combined with the deep technical expertise of our scientific community will allow us to better serve our partners to rapidly generate and assess data to understand complex molecules, along with the processes used in their manufacture.”
 
The BIC originally opened in May 2016 as a three-story, 62,000 square foot facility with the purpose of process invention, process design and development, and product characterization for Fujifilm Diosynth Biotechnologies’ clients.